The phase III trial, being conducted in Europe and Canada, is investigating the safety and efficacy of TH-070 in patients with benign prostatic hyperplasia (BPH). Approximately 500 patients are participating in the study for up to four and a half months.
The primary objective of this study is to evaluate the efficacy of TH-070 compared to placebo as measured by IPSS (International Prostate Symptom Score) in subjects with symptomatic BPH.
“Now that enrollment has been completed in both the phase II and phase III TH-070 trials, we plan to have top line results from these trials around the beginning of the fourth quarter of this year,” said Dr Alan Colowick, chief medical officer at Threshold. “Rapid enrollment into both of these trials reflects the enthusiasm and support of the clinical investigators and their staff who are dedicated to finding improved treatment options for their patients with BPH.”